Quarterly Records: AVISE ® CTD Volumes, Ordering Healthcare Providers and Adopters SAN DIEGO , May 11, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2021 .

The suite of innovative biomarker assays seeks to further aid clinicians in the diagnosis, prognosis and monitoring of patients with autoimmune diseases SAN DIEGO , May 04, 2021 (GLOBE NEWSWIRE) -- Exagen Inc.  (Nasdaq: XGN), a leading provider of autoimmune testing solutions, Allegheny Health

SAN DIEGO , May 03, 2021 (GLOBE NEWSWIRE) -- Exagen Inc.  (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of awareness initiatives and educational tools highlighting the importance of an accurate and timely

SAN DIEGO , April 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2021 after the market close on Tuesday, May 11, 2021 . Ron Rocca , Exagen’s President and Chief Executive

SAN DIEGO , March 29, 2021 (GLOBE NEWSWIRE) -- Exagen Inc.  (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that it will collaborate with Emory University on a new study about the long-term effects of

SAN DIEGO , March 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has closed its previously announced underwritten public offering of 4,255,000 shares of its common stock, including 555,000 shares sold pursuant to

SAN DIEGO , March 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of an underwritten public offering of 3,700,000 shares of its common stock at a price to the public of $16.25 per share.

SAN DIEGO , March 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.

Quarterly Records: Revenue, Gross Margin, AVISE® CTD Volumes and Adopters SAN DIEGO , March 16, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2020 .

SAN DIEGO , March 02, 2021 (GLOBE NEWSWIRE) -- Exagen Inc.  (Nasdaq: XGN), a leading autoimmune organization, will release financial results for the quarter and year ended December 31, 2020 after the market close on Tuesday, March 16, 2021 . Ron Rocca , President and Chief Executive Officer, and